NUZ · ASX

Neurizon Therapeutics Limited (ASX:NUZ)

AU$0.14

 0.0 (0.0%)
ASX:Live
09/05/2025 02:45:34 PM
HALO Price Momentum HALO Ords GROWTH AUS Engulfing Bullish All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NUZ Overview

NUZ Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NUZ

Website

Neurizon Therapeutics Limited

Telephone

61.3.9692.7222

Address

Level 4 96-100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.

NUZ Price Chart

Key Stats

Market Cap

AU$68.92M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.26

Trade Value (12mth)

AU$35,142.00

1 week

0%

1 month

45.83%

YTD

-15.15%

1 year

-22.22%

All time high

4.74

Key Fundamentals

EPS 3 yr Growth

481.00%

EBITDA Margin

N/A

Operating Cashflow

-$5m

Free Cash Flow Return

-68.90%

ROIC

-118.60%

Interest Coverage

N/A

Quick Ratio

12.40

Other Data

Shares on Issue (Fully Dilluted)

483m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

NUZ Announcements

Latest Announcements

Date Announcements

06 May 25

Neurizon to present Q3 FY2025 Results

×

Neurizon to present Q3 FY2025 Results

05 May 25

Last Patient Successfully Completes Treatment in OLE Study

×

Last Patient Successfully Completes Treatment in OLE Study

28 April 25

Appendix 4C & Quarterly Update

×

Appendix 4C & Quarterly Update

24 April 25

Notice of Quarterly Shareholder Update Webinar

×

Notice of Quarterly Shareholder Update Webinar

22 April 25

Appointment of Chief Financial Officer

×

Appointment of Chief Financial Officer

17 April 25

Leadership team strengthened with strategic appointments

×

Leadership team strengthened with strategic appointments

04 April 25

NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells

×

NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells

01 April 25

NUZ-001 Shows Positive Results in Human 3D Brain Model

×

NUZ-001 Shows Positive Results in Human 3D Brain Model

24 March 25

NUZ-001 shows promising respiratory outcome

×

NUZ-001 shows promising respiratory outcome

17 March 25

Neurizon Commences Initiatives to Lift Clinical Hold

×

Neurizon Commences Initiatives to Lift Clinical Hold

17 February 25

Neurizon to Present Latest Results and Key Updates

×

Neurizon to Present Latest Results and Key Updates

17 February 25

FDA Guidance on NUZ-001 IND Application

×

FDA Guidance on NUZ-001 IND Application

17 February 25

Appendix 4D - Half-year Financial Report - 31 December 2024

×

Appendix 4D - Half-year Financial Report - 31 December 2024

11 February 25

Notice of Company Update Webinar

×

Notice of Company Update Webinar

07 February 25

Change of Director's Interest Notices x3

×

Change of Director's Interest Notices x3

05 February 25

US Patent granted for NUZ-001

×

US Patent granted for NUZ-001

31 January 25

Notification regarding unquoted securities - NUZ

×

Notification regarding unquoted securities - NUZ

29 January 25

Appendix 4C & Quarterly Update

×

Appendix 4C & Quarterly Update

17 January 25

Neurizon updates on NUZ-001 IND Application

×

Neurizon updates on NUZ-001 IND Application

16 January 25

Change of Share Registry

×

Change of Share Registry

27 December 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

27 December 24

Application for quotation of securities - NUZ

×

Application for quotation of securities - NUZ

18 December 24

Neurizon Files IND Application to Support HEALEY ALS Trial

×

Neurizon Files IND Application to Support HEALEY ALS Trial

17 December 24

Neurizon Granted OMPD for NUZ-001 in Europe

×

Neurizon Granted OMPD for NUZ-001 in Europe

16 December 24

Positive 8-month Interim Data from OLE Study

×

Positive 8-month Interim Data from OLE Study

NUZ Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.02 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.02 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.6 -259.3 -25.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -67.8 -17.0 -134.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -6.2 -6.6 -7.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.01 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.5 -84.9 921.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 317 321 371 Lock Lock Lock
Basic m Lock Lock Lock Lock 317 321 371 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 3 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 58.0 -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 3 7 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 71.0 100.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -6.6 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 107 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -3 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.3 -3.6 -164.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -72.0 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.5 8.3 -164.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -81.3 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -2 -2 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -6 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.7 -263.6 -45.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -50.5 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -2 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 2 13 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -2 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.3 -16.2 -223.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.4 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 3 10 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 10 6 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 -2 -10 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 4 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 9 5 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.3 -46.2 114.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -16.9 -101.3 -81.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -159.7 -88.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -28.4 -35.6 -87.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -18.1 -23.0 -118.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -14.1 -22.9 -68.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -27.5 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.4 0.7 1.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -13.2 -42.7 -95.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.2 2.2 12.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.3 2.2 12.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 64.9 89.7 87.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -114.3 -116.1 -576.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 14.5 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.5 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.3 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 17.9 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -50.5 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -16.9 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -16.9 -101.3 -81.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.6 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -159.7 -88.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -21.8 -159.7 -88.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 103.8 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 25.1 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 129.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 58.3 0.0 192,105.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 70.7 0.0 -192,105.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NUZ Shortsell

Frequently Asked Questions

The current share price of Neurizon Therapeutics Limited (NUZ:ASX) is AU$0.14.
The 52-week high share price for Neurizon Therapeutics Limited (NUZ:ASX) is AU$0.26.
The 52-week low share price for Neurizon Therapeutics Limited (NUZ:ASX)? is AU$0.10.
Neurizon Therapeutics Limited (NUZ:ASX) does not pay a dividend.
Neurizon Therapeutics Limited (NUZ:ASX) does not pay a dividend.
Neurizon Therapeutics Limited (NUZ:ASX) has a franking level of 0.0%.
Neurizon Therapeutics Limited (NUZ:ASX) is classified in the Healthcare.
The current P/E ratio for Neurizon Therapeutics Limited (NUZ:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.